105 related articles for article (PubMed ID: 21833446)
1. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event.
Mahan CE; Holdsworth MT; Welch SM; Borrego M; Spyropoulos AC
Thromb Haemost; 2011 Sep; 106(3):405-15. PubMed ID: 21833446
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States.
Caprini JA; Botteman MF; Stephens JM; Nadipelli V; Ewing MM; Brandt S; Pashos CL; Cohen AT
Value Health; 2003; 6(1):59-74. PubMed ID: 12535239
[TBL] [Abstract][Full Text] [Related]
4. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and cost of deep venous thrombosis among patients with cancer.
Elting LS; Escalante CP; Cooksley C; Avritscher EB; Kurtin D; Hamblin L; Khosla SG; Rivera E
Arch Intern Med; 2004 Aug 9-23; 164(15):1653-61. PubMed ID: 15302635
[TBL] [Abstract][Full Text] [Related]
6. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery.
Nutescu EA; Shorr AF; Farrelly E; Horblyuk R; Happe LE; Franklin M
Ann Pharmacother; 2008 Sep; 42(9):1216-21. PubMed ID: 18611992
[TBL] [Abstract][Full Text] [Related]
7. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
8. European Union-28: An annualised cost-of-illness model for venous thromboembolism.
Barco S; Woersching AL; Spyropoulos AC; Piovella F; Mahan CE
Thromb Haemost; 2016 Apr; 115(4):800-8. PubMed ID: 26607486
[TBL] [Abstract][Full Text] [Related]
9. The use of pharmacoeconomics in formulary development: can this improve the way deep vein thrombosis is treated?
White TJ
Am J Manag Care; 2001 Nov; 7(17 Suppl):S545-50; discussion S550-2. PubMed ID: 11732665
[TBL] [Abstract][Full Text] [Related]
10. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
12. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective.
de Lissovoy G
Am J Manag Care; 2001 Nov; 7(17 Suppl):S535-8; discussion S538-44. PubMed ID: 11732664
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
15. Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association
Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.
Grosse SD; Nelson RE; Nyarko KA; Richardson LC; Raskob GE
Thromb Res; 2016 Jan; 137():3-10. PubMed ID: 26654719
[TBL] [Abstract][Full Text] [Related]
17. The economic costs of pain in the United States.
Gaskin DJ; Richard P
J Pain; 2012 Aug; 13(8):715-24. PubMed ID: 22607834
[TBL] [Abstract][Full Text] [Related]
18. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Cost of Deep Vein Thrombosis in Emergency General Surgery Over 15 Years.
Gantz O; Mulles S; Zagadailov P; Merchant AM
J Surg Res; 2020 Aug; 252():125-132. PubMed ID: 32278966
[TBL] [Abstract][Full Text] [Related]
20. Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ; Scuffham PA; McCollam PL; Newby DE
Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
